Cardiol Therapeutics wins US patent protection for heart-disease drug platform
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
AGA affects up to 80 per cent of men across their lifetime and remains one of the most common and most psychologically challenging forms of hair loss
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Subscribe To Our Newsletter & Stay Updated